We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Novel Psychoactive Substances Committee (NPSC) is seeking evidence for its review of the evidence of the misuse and harms of synthetic cathinones in the UK.
The government responds to the ACMD's report on recently encountered novel benzodiazepines and related compounds.
Professor Owen Bowden-Jones, Chair, Advisory Council on the Misuse of…
Government response to the report by the Advisory Council on the Misuse of Drugs on acyl piperazine opioids, including 2-methyl-AP-237.
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.
The government commissions the Advisory Council on the Misuse of Drugs (ACMD) to review the fees applicable under the hemp licensing regime.
ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD).
A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).
This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.
Government response to the report by the Advisory Council on the Misuse of Drugs on xylazine, medetomidine and detomidine.
Fifteen additional synthetic opioids are now under the strictest controls to prevent drug related deaths and ensure anyone caught supplying them faces tough penalties.
Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.
Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.
The Advisory Council on the Misuse of Drugs (ACMD) seeks to gather insight into current government-led drug prevention policies and landscape across the UK.
The Advisory Council on the Misuse of Drugs call for evidence, collecting written evidence to better understand internet-facilitated drug markets (IFDMs).
Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.
The government responds to a report by the Advisory Council on the Misuse of Drugs and commissions Part 2 of work on barriers to research.
The government responds to a report by the Advisory Council on the Misuse of Drugs (ACMD) regarding NHS England proposals on electronic prescribing.
The Advisory Council on the Misuse of Drugs has undertaken a review of the availability and implementation of naloxone in the UK.
The ACMD will use your response to help them formulate advice to government about drug use in ethnic minority groups.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).